Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

Lung Cancer

Volumn 84, Issue 1, 2014, Pages 62-66

  Heigener, D F ^a   Deppermann, K M ^b   Pawel, J v ^c   Fischer, J R ^d   Kortsik, C ^e   Bohnet, S ^f   Eiff, M v ^g   Koester, W ^h   Thomas, M ⁱ   Schnabel, P A ⁱ   Reck, M ^a  

^a Member of the German Center for Lung Research   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

^c Asklepios Klinikum Gauting   (Germany)

^d Klinik Lowenstein   (Germany)

^e St Hildegardis Krankenhaus   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g Malteser Hildegardis Krankenhaus Köln   (Germany)

^h KLINIKEN ESSEN MITTE   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Elderly; Erlotinib; NSCLC

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE;

AGED; ARTICLE; BONE MARROW TOXICITY; BULLOUS DERMATITIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

CHEMOTHERAPY; ELDERLY; ERLOTINIB; NSCLC;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84896713766     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.024     Document Type: Article

References (12)

1. Gesundheit in Deutschland Gesundheitsberichterstattung des Bundes 2006, Gesundheit in Deutschland, Berlin.
2. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2191-2197.
3. Gridelli C. The ELVIS trial: a phase III study of single-agent Vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 6(Suppl 1):4-7.
4. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
5. Heigener D.F., Wu Y.L., van Z.N., Mali P., Horwood K., Reck M. Second-line Erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer 2011, 74(2):274-279.
6. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818.
7. Clark G.M., Zborowski D.M., Santabarbara P., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from Erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006, 7(6):389-394.
8. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
9. Giaccone G., Gallegos R.M., Le C.T., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006, 12(20 Pt 1):6049-6055.
10. Gridelli C., Ciardiello F., Gallo C., et al. First-line Erlotinib followed by second-line Cisplatin-Gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30(24):3002-3011.
11. Quoix E., Zalcman G., Oster J.P., et al. Carboplatin and weekly Paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378(9796):1079-1088.
12. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.